177 related articles for article (PubMed ID: 35177990)
1. Potentially Hazardous Drug-Drug Interactions Associated With Oral Antineoplastic Agents Prescribed in Chinese Tertiary Care Teaching Hospital Settings: A Multicenter Cross-Sectional Study.
Wang H; Shi H; Wang Y; Wang N; Li Y; Yang Q; Li Y; Liu C; Zan Y; Feng S; Xie J
Front Pharmacol; 2022; 13():808848. PubMed ID: 35177990
[No Abstract] [Full Text] [Related]
2. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study.
Ko Y; Tan SL; Chan A; Wong YP; Yong WP; Ng RC; Lim SW; Salim A
Clin Ther; 2012 Aug; 34(8):1696-704. PubMed ID: 22795926
[TBL] [Abstract][Full Text] [Related]
3. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: A prospective study in a tertiary care teaching hospital.
Ramasubbu SK; Mahato SK; Agnihotri A; Pasricha RK; Nath UK; Das B
Cancer Treat Res Commun; 2021; 26():100277. PubMed ID: 33348276
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions.
van Leeuwen RWF; Jansman FGA; van den Bemt PMLA; de Man F; Piran F; Vincenten I; Jager A; Rijneveld AW; Brugma JD; Mathijssen RHJ; van Gelder T
Ann Oncol; 2015 May; 26(5):992-997. PubMed ID: 25628444
[TBL] [Abstract][Full Text] [Related]
5. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists.
Chan A; Tan SH; Wong CM; Yap KY; Ko Y
Clin Ther; 2009; 31 Pt 2():2379-86. PubMed ID: 20110047
[TBL] [Abstract][Full Text] [Related]
6. Mitigating the Risk of Drug Interactions in Cancer Patients Taking Oral Anticancer Agents: The Role of a Multidisciplinary Team-Based Medication Reconciliation.
Rodrigues J; Marques P; Gomes C; Portela C
Cureus; 2023 Feb; 15(2):e35324. PubMed ID: 36994248
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of potential drug - drug interactions in the cardiothoracic intensive care unit patients in a Chinese tertiary care teaching hospital.
Wang H; Shi H; Wang N; Wang Y; Zhang L; Zhao Y; Xie J
BMC Pharmacol Toxicol; 2022 Jun; 23(1):39. PubMed ID: 35701808
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.
Khan Q; Ismail M; Haider I; Khan F
Int J Clin Pharm; 2017 Dec; 39(6):1256-1264. PubMed ID: 28895028
[TBL] [Abstract][Full Text] [Related]
9. Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study.
Kim SH; Suh Y; Ah YM; Jun K; Lee JY
Support Care Cancer; 2020 Aug; 28(8):3617-3626. PubMed ID: 31802250
[TBL] [Abstract][Full Text] [Related]
10. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.
Khan Q; Ismail M; Khan S
BMC Pharmacol Toxicol; 2017 Dec; 18(1):75. PubMed ID: 29191244
[TBL] [Abstract][Full Text] [Related]
11. Potential Drug - Drug Interactions among Medications Prescribed to Hypertensive Patients.
Kothari N; Ganguly B
J Clin Diagn Res; 2014 Nov; 8(11):HC01-4. PubMed ID: 25584241
[TBL] [Abstract][Full Text] [Related]
12. Nationwide prevalence of potential drug-drug interactions associated with non-anticancer agents in patients on oral anticancer agents in South Korea.
Song YK; Oh JM
Support Care Cancer; 2020 Aug; 28(8):3711-3720. PubMed ID: 31820128
[TBL] [Abstract][Full Text] [Related]
13. Clinically important potential drug-drug interactions in outpatient settings.
Aparasu R; Baer R; Aparasu A
Res Social Adm Pharm; 2007 Dec; 3(4):426-37. PubMed ID: 18082877
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications.
Patel D; Bertz R; Ren S; Boulton DW; Någård M
Clin Pharmacokinet; 2020 Apr; 59(4):447-462. PubMed ID: 31788764
[TBL] [Abstract][Full Text] [Related]
15. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers.
Ko Y; Malone DC; Skrepnek GH; Armstrong EP; Murphy JE; Abarca J; Rehfeld RA; Reel SJ; Woosley RL
Drug Saf; 2008; 31(6):525-36. PubMed ID: 18484786
[TBL] [Abstract][Full Text] [Related]
16. Proton Pump Inhibitors and Cancer: Current State of Play.
Bridoux M; Simon N; Turpin A
Front Pharmacol; 2022; 13():798272. PubMed ID: 35359844
[No Abstract] [Full Text] [Related]
17. Drug-drug interactions in pediatric oncology patients.
Balk TE; van der Sijs IH; van Gelder T; Janssen JJB; van der Sluis IM; van Leeuwen RWF; Engels FK
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28205376
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and associated factors of drug-drug interactions in elderly outpatients in a tertiary care hospital: a cross-sectional study based on three databases.
Liu Y; Wang J; Gong H; Li C; Wu J; Xia T; Li C; Li S; Chen M
Ann Transl Med; 2023 Jan; 11(1):17. PubMed ID: 36760261
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoepidemiological study of drug-drug interactions in onco-hematological pediatric patients.
Fernández de Palencia Espinosa MA; Díaz Carrasco MS; Fuster Soler JL; Ruíz Merino G; De la Rubia Nieto MA; Espuny Miró A
Int J Clin Pharm; 2014 Dec; 36(6):1160-9. PubMed ID: 25204258
[TBL] [Abstract][Full Text] [Related]
20. Assessment of prescribed medications and pattern of distribution for potential drug-drug interactions among chronic kidney disease patients attending the Nephrology Clinic of Lagos University Teaching Hospital in Sub-Saharan West Africa.
Fasipe OJ; Akhideno PE; Nwaiwu O; Adelosoye AA
Clin Pharmacol; 2017; 9():125-132. PubMed ID: 29123429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
